Show simple item record

dc.contributor.authorBremell, Daniel
dc.date.accessioned2014-05-05T06:42:38Z
dc.date.available2014-05-05T06:42:38Z
dc.date.issued2014-05-05
dc.identifier.isbn978-91-628-8950-0
dc.identifier.isbn978-91-628-9034-6
dc.identifier.urihttp://hdl.handle.net/2077/35202
dc.description.abstractLyme neuroborreliosis, the infection of the nervous system by the tick-borne bacterium Borrelia burgdorferi, is a common infection in the temperate parts of the Northern hemisphere. Manifestations of the disease include facial palsy, radicular pain, sensory disturbances, and occasionally CNS symptoms such as confusion and paraparesis. The diagnosis of Lyme neuroborreliosis is based on medical history, clinical examination and cerebrospinal fluid (CSF) analysis. Recommended antibiotic treatment is oral doxycycline or intravenous ceftriaxone. The overall aims of this thesis were to improve the diagnosis and treatment of Lyme neuroborreliosis. In paper I, 102 patients with peripheral facial palsy were studied. Onset of symptoms in July to October, additional neurological symptoms and CSF pleocytosis were factors that discriminate patients with peripheral facial palsy caused by Lyme neuroborreliosis from patients with Bell’s palsy. In paper II, it was shown that CSF levels of the chemokine CXCL13 are highly elevated in Lyme neuroborreliosis and that levels decline after treatment, but high and overlapping CXCL13 levels were also seen in patients with asymptomatic HIV-infection and the decrease in CXCL13 is correlated to the decrease in CSF cell count. The additional diagnostic value of CXCL13 analysis is therefore limited. In paper III, new reference ranges for CSF cell counts when analyzed with automatic cell counters were determined, based on CSF sampling of 80 healthy volunteers. The differentiation of mononuclear cells into lymphocytes and monocytes was shown to be of limited value in the discrimination between Lyme neuroborreliosis and viral CNS infections. In paper IV, it was shown that treatment with oral doxycycline resulted in a similar decrease in CSF mononuclear cell counts in patients with Lyme neuroborreliosis with CNS symptoms compared with patients with peripheral nervous systems symptoms, and that all patients with CNS symptoms improved on treatment with no need for retreatment. Oral doxycycline can therefore be considered an effective treatment for Lyme neuroborreliosis, irrespective of the severity of symptoms.sv
dc.language.isoengsv
dc.relation.haspartBremell D, Hagberg L. Clinical characteristics and cerebrospinal fluid parameters in patients with peripheral facial palsy caused by Lyme neuroborreliosis compared with facial palsy of unknown origin (Bell's palsy). BMC Infectious Diseases. 2011;11:215. ::doi::10.1186/1471-2334-11-215sv
dc.relation.haspartBremell D, Mattsson N, Edsbagge M, Blennow K, Andreasson U, Wikkelsö C, Zetterberg H, Hagberg L. Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection. BMC Neurology. 2013;13:2. ::doi::10.1186/1471-2377-13-2sv
dc.relation.haspartBremell D, Mattsson N, Wallin F, Henriksson J, Wall M, Blennow K, Zetterberg H, Hagberg L. Automated cerebrospinal fluid cell count - New reference ranges and evaluation of its clinical use in central nervous system infections. Clinical Biochemistry. 2014; 47(1-2):25–30. ::doi::10.1016/j.clinbiochem.2013.11.010sv
dc.relation.haspartBremell D, Dotevall L. Oral doxycycline for Lyme neuroborreliosis with symptoms of encephalitis, myelitis, vasculitis or intracranial hypertension. European Journal of Neurology. Epub ahead of print. ::doi::10.1111/ene.12420sv
dc.subjectLyme diseasesv
dc.subjectLyme borreliosissv
dc.subjectLyme neuroborreliosissv
dc.subjectBorrelia burgdorferisv
dc.subjectfacial palsysv
dc.subjectdoxycyclinesv
dc.subjectchemokine CXCL13sv
dc.subjectcell countsv
dc.titleLyme Neuroborreliosis - Diagnosis and Treatmentsv
dc.typetexteng
dc.type.svepDoctoral thesiseng
dc.gup.maildaniel.bremell@infect.gu.sesv
dc.type.degreeDoctor of Philosophy (Medicine)sv
dc.gup.originUniversity of Gothenburg. Sahlgrenska Academysv
dc.gup.departmentInstitute of Biomedicine. Department of Infectious Diseasessv
dc.gup.defenceplaceTorsdagen den 22 maj 2014, kl 13.00. Föreläsningssalen, Infektionskliniken, Sahlgrenska universitetssjukhuset/Östrasv
dc.gup.defencedate2014-05-22
dc.gup.dissdb-fakultetSA


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record